Our activities were also focused on research and development of biologically active small molecules, some of them were licensed to big pharma (anti-obesitic peptides to NovoNordisk), while others successfully continue preclinical and clinical development. We have established effective collaboration with industry, trained academic researchers in development of candidate drugs and diagnostics, established regular evaluation processes in collaboration with PerMed Science Addvisory Board, funded communication strategy and concentrated technology transfer and regulatory knowledge under one umbrella. In the course of PerMed realization, we have understood the importance of early recognition of clinical needs, development of innovative solutions and their validation in real world settings, the process called translational science. The research and management team would like to further advance personalized medicine solutions via translational sciences in the Czech Republic within the proposed project PerMed: T2BA.

We have re-structuralized the research teams and individual projects according to current needs. In particular, projects involving bioinformatics, laboratory informatics, artificial intelligence, telemedicine and molecular imaging and tracing were included to address market and society needs. New rules also enable direct participation of small, medium and large enterprises, which empowers even closer collaboration and joint research. As illustrated in Figure 1, research activites are concentrated around Prague, Brno and Olomouc regions, known to actively pursuing biomedical research. Project strategic outlook and prospects in the field are summarized below.

Project partners and their geographic distribution